Highlights

  • Recruitment and dosing restarted for the final cohort of the pivotal Phase III insomnia trial.
  • About 320 more participants are expected, toward the original target of 519 completing the study.
  • The interim safety review found no serious adverse events among the first 244 participants.
  • Cash was $5.3 million at 30 September 2026, with licensing discussions continuing.

Avecho Biotechnology Limited (ASX:AVE) has released its quarterly activities report and Appendix 4C for the quarter ended 30 September 2026. The key development was the restart of recruitment and dosing for the final cohort of its pivotal Phase III trial of a CBD capsule for insomnia.

Phase III Insomnia Trial Progress

Following a positive interim analysis in June 2026, the independent Data Monitoring Board unanimously recommended continuing the trial to the original 519 participants, with no increase in sample size. The company remains blinded to treatment allocations and efficacy results.

About 320 additional participants are expected to be recruited. Participants receive nightly 75mg CBD, 150mg CBD or placebo for eight weeks. The interim safety review found no serious adverse events among the first 244 participants. Avecho expects enrolment to finish within about 12 months of additional sites becoming operational, and successful completion would be the final clinical step before a TGA registration application.

Intellectual Property and Business Development

A Japanese patent covering the TPM-enhanced CBD capsule was granted during the quarter, adding to US and European patents. Protection runs to 2043 in the US and 2041 in Europe and Japan.

Eve Williamson, formerly Vice President, Global Head of Business Development at CSL, was appointed as a strategic business development consultant. Licensing discussions with multiple pharmaceutical companies for territories outside Australia are progressing, and the company will present at BIO-Europe in November 2026. Work with Sandoz on the TGA submission has also accelerated.

Financial Position

Avecho held $5.3 million in cash at 30 September 2026, down from $6.6 million at 30 June 2026. Net operating cash outflow was $1.77 million, while financing inflows of $457,000 included a $477,000 R&D loan receipt.

The estimated funding runway is 2.98 quarters. Non-dilutive licensing funding is the company's preferred way to pay for activating additional trial sites.

Key Takeaways

  • The Phase III trial is back on track toward its original 519-participant target.
  • No serious adverse events were reported in the interim safety review.
  • Patent protection has expanded to Japan.
  • Licensing deals are the preferred source of funding for further trial sites.